Arctic Bioscience — Regulatory Filings 2025

Nov 4, 2025

Arctic Bioscience - Analysis on HeROPA study shows statistically significant effects of psoriasis drug candidate HRO350 on inflammation

Arctic Bioscience - Analysis on HeROPA study shows statistically significant effects of psoriasis drug candidate HRO350 on inflammation

Analysis on blood samples from the psoriasis HeROPA-trial revealed statistically

significant effects of HRO350 versus placebo on Systemic Immune-inflammation

Index (SII) in patients with mild-to-moderate psoriasis. Significantly more

patients treated with HRO350 achieved a ? 25% reduction in a systemic

inflammatory marker at both 26 weeks and 1 year compared to placebo. Among

patients with lower baseline systemic inflammation, this reduction was

accompanied by statistically significant improvements in psoriasis skin symptoms

and quality of life, shown through achievement of sPGA0/1 and DLQI0/1 in the

HRO350 group after 1 year.

The results show that patient screening based on baseline SII in mild-to

-moderate psoriasis may reduce the inherent uncertainty in the patient target

group for HRO350 in further development phase. Inflammation plays a key role in

psoriasis and can be measured through biomarkers. Systemic inflammation measured

in blood provides a distinct perspective on disease severity compared to skin

symptoms. These findings on the impact of HRO350 on inflammation aligns with in

vitro cellular data indicating involvement of HRO350 in resolution of

inflammation.

"These new findings showing the potential of HRO350 in reducing inflammation are

of significant value for Arctic Bioscience. The data strengthens a further

development within mild-to-moderate psoriasis, as well as the potential of

general effects on inflammation which may strengthen our HRO350-asset. The

findings from these analyses will also be important as we now enter commercial

dialogues with potential partners", says Christer Valderhaug, CEO.

The Systemic Immune-inflammation Index (SII) is a biomarker which reflects

systemic inflammation and immune status. SII has been found to correlate with

psoriasis severity, risk of disease activation, and decreases with effective

systemic therapy.

"Psoriasis is an inflammatory skin disease, which is associated with premature

cardiovascular disease. SII is a measure of systemic inflammation, which is an

independent risk factor for cardiovascular disease. A high SII is associated

with treatment resistance to even highly effective biologic drugs. For the

patients with a lower amount of inflammation in the HeROPA trial, the drug is

working. The treatment shows a difference to placebo in patients with lower

inflammation - and it lowers inflammation in all patients, which may also be

beneficial for long term cardiovascular health", says Professor Brian Kirby,

Ireland, who has served on the Data Monitoring Committee for the HeROPA trial.

The HeROPA study is a phase 2b study investigating efficacy and safety of HRO350

in mild-to-moderate psoriasis and included over 500 patients in five countries.

HRO350 was well tolerated throughout the study, with no safety concerns or drug

-related serious adverse events reported. All the patients in the HeROPA trial

had mild-to-moderate psoriasis as assessed by their skin symptoms (PASI < 10).

However, a significant portion of the patients had an SII at start that could be

associated with more severe inflammation.

Psoriasis is a chronic, immune-mediated inflammatory disease. If untreated,

subclinical inflammation may increase patients' risks for disease progression to

severe psoriasis. Early treatment intervention for psoriasis may help reducing

risk of developing multiple comorbidities, including psoriatic arthritis.

Arctic Bioscience strongly believe there is a major market potential for HRO350

in mild-to-moderate psoriasis and will seek partnerships for further

development.

Significant effects on systemic inflammation, particularly among patients with

lower baseline systemic inflammation, suggest platform potential for HRO350. The

observed anti-inflammatory activity positions HRO350 as a potential treatment

option for inflammatory conditions.

Please see attachment for more details and results from the analyses conducted.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

E-mail: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.